drugset
Drugs / iode 131
last change Aug 2023 re-read 9 days ago

iode 131

English name Iodine-131
also known as (131)I · radioactive iodine · radioiodine
Developed for
thyroid cancer
Investigated by
Gustave Roussy, Cancer Campus, Grand Paris · National Cancer Institute, France

Trials 1

today NCT00435851 · Ph 3
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 3 NCT00435851 Feb 2007 → ? thyroid cancer Gustave Roussy, Cancer Campus, Grand Paris Unknown Met primary

Press releases naming this drug 21 releases

DateIssuerRelease
2023-08-15 Ipsen Ipsen receives positive CHMP opinion for Cabometyx® in radioactive iodine-refractory differentiated thyroid cancer ipsen.com ↗
2022-05-03 Ipsen European Commission approves Cabometyx® as a second-line treatment for people living with radioactive iodine-refractory differentiated thyroid cancer ipsen.com ↗
2022-05-03 Exelixis Exelixis’ Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer exelixis.com ↗
2022-03-25 Ipsen Ipsen receives positive CHMP opinion for Cabometyx® in radioactive iodine-refractory differentiated thyroid cancer ipsen.com ↗
2022-03-25 Exelixis Exelixis’ Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer exelixis.com ↗
2021-09-20 Exelixis Exelixis Announces Final Results from Phase 3 COSMIC-311 Pivotal Trial of CABOMETYX® in Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer Presented at ESMO 2021 exelixis.com ↗
2021-09-17 Exelixis Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer exelixis.com ↗
2021-08-05 Exelixis Exelixis Announces U.S. FDA Accepts for Priority Review the Supplemental New Drug Application for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer exelixis.com ↗
2021-06-07 Exelixis Exelixis and Ipsen Announce Detailed Results from Phase 3 COSMIC-311 Pivotal Trial of Cabozantinib in Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer Presented at ASCO 2021 exelixis.com ↗
2021-02-25 Exelixis Exelixis Announces Breakthrough Therapy Designation Granted to Cabozantinib for the Treatment of Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer exelixis.com ↗
2020-12-21 Exelixis Exelixis Announces Cabozantinib Significantly Improved Progression-Free Survival in COSMIC-311 Phase 3 Pivotal Trial in Patients with Previously Treated Radioiodine-Refractory Differentiated Thyroid Cancer exelixis.com ↗
2020-02-25 Exelixis Exelixis Announces First 100 Patients Enrolled in Phase 3 COSMIC-311 Pivotal Trial of Cabozantinib in Relapsed Radioiodine-Refractory Differentiated Thyroid Cancer exelixis.com ↗

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as iode 131 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00435851 ↗
Known as (131)I “we compared two thyrotropin-stimulation methods (thyroid hormone withdrawal and use of recombinant human thyrotropin) and two radioiodine ((131)I) doses (i.e., administered...” PMID 22551127 ↗ May 2012
Known as radioactive iodine “In ESTIMABL1, a randomised phase 3 trial of radioactive iodine (131I) administration after complete surgical resection in patients with low-risk thyroid cancer” PMID 29807824 ↗ May 2018
Known as radioiodine “we compared two thyrotropin-stimulation methods (thyroid hormone withdrawal and use of recombinant human thyrotropin) and two radioiodine ((131)I) doses (i.e., administered...” PMID 22551127 ↗ May 2012